안구건조증 환자에서 사이클로스포린 0.05% 점안액의 임상효과

• 영문명: Clinical Effect of Cyclosporine 0.05% Eye Drops in Dry Eye Syndrome Patients
• 발행기관: 대한안과학회
• 저자명: 변용수 전은정 정성근,Yong Soo Byun, M.D., Eun Jeong Jeon, M.D., Ph.D., Sung Kun Chung, M.D., Ph.D.
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume49,number10, 1583~1588쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2008.10.15

영문 초록

Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after using Restasis^{® (Cyclosporine 0.05% ophthalmic emulsion, Allergan Inc., U.S.A.). Methods: We randomly selected 39 patients from newly or previously diagnosed dry eye syndrome patients and administered Restasis® to them. We checked their clinical parameters and symptoms over a period of 3 months. The clinical parameters evaluated were type I and type II Schirmer tests and tear break-up time, and the symptoms of dry eye syndrome were classified into pain, itching, foreign body sensation, blurred vision, and photophobia using a scoring scale for symptoms of 0 to 5. The results were analyzed with a Mann-Whitney test (P-values <0.05 was considered statistically significant). Results: For 26 of 39 patients (52 eyes) on whom all tests were carried out for 3 months, there was a significant improvement after 3 months in the type I Schirmer test, type II Schirmer test, and tear break-up time (P=0.012, 0.009, 0.001, respectively). Only 14 patients completed the questionnaire for scoring of symptoms. After using Restasis®, foreign body sensation only improved (P=0.010). Conclusions: In our study, tear secretion was increased by Restasis®, and a greater increase in tear secretion was seen in patients with systemic disease than in patients without systemic disease. Additional patients need to be evaluated and longer-term studies need to be performed to confirm our results. J Korean Ophthalmol Soc 2008;49(10):1583-1588}

키워드

Cyclosporine, Dry eye syndrome, Restasis